Stock Price Quote

WINDLAS BIOTECH LTD.

NSE : WINDLASBSE : 543329ISIN CODE : INE0H5O01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE551.50-0.4 (-0.07 %)
PREV CLOSE ( ) 551.90
OPEN PRICE ( ) 559.85
BID PRICE (QTY) 550.45 (7)
OFFER PRICE (QTY) 552.70 (7)
VOLUME 96
TODAY'S LOW / HIGH ( )551.50 559.85
52 WK LOW / HIGH ( )250.1 590
NSE553.500.75 (+0.14 %)
PREV CLOSE( ) 552.75
OPEN PRICE ( ) 547.00
BID PRICE (QTY) 552.75 (30)
OFFER PRICE (QTY) 553.50 (14)
VOLUME 425
TODAY'S LOW / HIGH( ) 547.00 555.15
52 WK LOW / HIGH ( )251 590.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-02 2001
Management Info
Vivek Dhariwal - Chairman Hitesh Windlass - Managing Director
Registered Office

Address 40 / 1,Mohabewala Industrial Area,,
Dehradun,
Uttarakhand-248110

Phone 0135-6608000-30

Email grievance@windlasbiotech.com

Website www.windlasbiotech.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

29Apr Windlas Biotech informs about analyst
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..
03Apr Windlas Biotech surges on commissionin
Windlas Biotech is currently trading at Rs. 562.85, up by 12.90 points o..
02Apr Windlas Biotech informs about press re
Windlas Biotech has informed that it attached press release on ‘Windlas..
02Apr Windlas Biotech commissions injectable
Windlas Biotech has commissioned its state-of-the-art injectable facilit..
20Feb Windlas Biotech informs about analyst
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit150.98426.44
Gross Profit 198.07 570.57
Operating Profit 235.01702.07
Net Sales 1622.135130.83

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  8424.25 (1.20%)
M.Cap ( in Cr)19170.92
Abbott India (BSE)
peergroup  26500.00 (0.32%)
M.Cap ( in Cr)56131.62
Neuland Laboratories (BSE)
peergroup  7663.95 (0.83%)
M.Cap ( in Cr)9751.68
Dr. Reddy's Lab (BSE)
peergroup  6244.05 (0.63%)
M.Cap ( in Cr)103512.40
NGL Fine-Chem (BSE)
peergroup  2572.75 (0.99%)
M.Cap ( in Cr)1573.91

Shareholding Pattern

PROMOTERS 62.82%
NON-INSTITUTION 24.19%
MUTUAL FUNDS/UTI 10.37%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Windlas Biotech Ltd.

Windlas Biotech Ltd. was incorporated in the year 2001. Its today's share price is 551.5. Its current market capitalisation stands at Rs 1147.87 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5130.83 Cr and Total Income of Rs.5230.48 Cr. The company's management includes Ananta Narayan Panda, Gaurav Gulati, Srinivasan Venkataraman, Vivek Dhariwal, Prachi Jain Windlass, Pawan Kumar Sharma, Manoj Kumar Windlass, Hitesh Windlass, Ashok Kumar Windlass.

It is listed on the BSE with a BSE Code of 543329 , NSE with an NSE Symbol of WINDLAS and ISIN of INE0H5O01029. It's Registered office is at 40 / 1,Mohabewala Industrial Area,Dehradun-248110, Uttarakhand. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are R Gupta & Associates, SS Kothari Mehta & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.